Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.
The National Comprehensive Cancer Network’s updated clinical practice guidelines for metastatic breast cancer retain bevacizumab as a treatment option and add two new therapies, the chemotherapy medicine eribulin and the RANKL inhibitor denosumab.
NEW YORK (Reuters Health) - Breast cancer screening that includes MRI scans might help find cancers at an earlier stage in high-risk women, reducing the likelihood that the tumors will become advanced before they're diagnosed, a new study suggests.
LONDON (Reuters) - Breast cancer patients who take the generic drug tamoxifen for five years are less likely to see their cancer return than those who take it for only two years, according to a large long-term study by British scientists.
FDA has agreed to Genentech’s request to revisit the agency’s decision to withdraw bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer. A public hearing is scheduled for June 28-29, and the resultant ruling is final.
NEW YORK (Reuters Health) - Older women who are diagnosed with early-stage breast cancer can expect to live just as long as peers without breast cancer, according to a new study.
Sentinel lymph node dissection was as effective as axillary lymph node surgery at lengthening lives but caused fewer painful side effects in this landmark study of women with invasive, early-stage breast cancer.
Early results from the Neo-ALTTO show that two medicines used together before surgery substantially increased response rates in HER2 positive early-stage breast cancer.
CHICAGO (Reuters) - Scientists know that being overweight increases the risk of breast cancers fed by estrogen, but being too fat may also increase the risk of triple-negative breast cancers, a less common and far more deadly type, U.S. researchers said on Tuesday.
CHICAGO (Reuters) - Breast cancer rates among U.S. white women have stopped falling, U.S. researchers said on Monday, suggesting that the fallout from a 2002 study linking hormone replacement therapy to breast cancer was short lived.